107 related articles for article (PubMed ID: 25872459)
21. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
Takahashi N; Miura M; Scott SA; Kagaya H; Kameoka Y; Tagawa H; Saitoh H; Fujishima N; Yoshioka T; Hirokawa M; Sawada K
J Hum Genet; 2010 Nov; 55(11):731-7. PubMed ID: 20720558
[TBL] [Abstract][Full Text] [Related]
22. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
Mizuarai S; Aozasa N; Kotani H
Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
[TBL] [Abstract][Full Text] [Related]
23. Associations between ABCG2 gene polymorphisms and isolated septal defects in a Han Chinese population.
Wang C; Xie L; Li H; Li Y; Mu D; Zhou R; Liu R; Zhou K; Hua Y
DNA Cell Biol; 2014 Oct; 33(10):689-98. PubMed ID: 24979295
[TBL] [Abstract][Full Text] [Related]
24. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
25. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
26. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.
Shafran A; Ifergan I; Bram E; Jansen G; Kathmann I; Peters GJ; Robey RW; Bates SE; Assaraf YG
Cancer Res; 2005 Sep; 65(18):8414-22. PubMed ID: 16166320
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia.
Wang F; Liang YJ; Wu XP; Chen LM; To KK; Dai CL; Yan YY; Wang YS; Tong XZ; Fu LW
Eur J Cancer; 2011 Sep; 47(13):1990-9. PubMed ID: 21531129
[TBL] [Abstract][Full Text] [Related]
28. Lipid regulation of the ABCB1 and ABCG2 multidrug transporters.
Hegedüs C; Telbisz Á; Hegedűs T; Sarkadi B; Özvegy-Laczka C
Adv Cancer Res; 2015; 125():97-137. PubMed ID: 25640268
[TBL] [Abstract][Full Text] [Related]
29. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
30. Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system.
Wakabayashi K; Nakagawa H; Adachi T; Kii I; Kobatake E; Kudo A; Ishikawa T
J Exp Ther Oncol; 2006; 5(3):205-22. PubMed ID: 16528971
[TBL] [Abstract][Full Text] [Related]
31. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Sparreboom A; Gelderblom H; Marsh S; Ahluwalia R; Obach R; Principe P; Twelves C; Verweij J; McLeod HL
Clin Pharmacol Ther; 2004 Jul; 76(1):38-44. PubMed ID: 15229462
[TBL] [Abstract][Full Text] [Related]
32. Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study.
Ferrari M; Romualdi E; Dentali F; Squizzato A; Marino F; Cosentino M; Ageno W
Thromb Res; 2014 Dec; 134(6):1359-62. PubMed ID: 25300812
[No Abstract] [Full Text] [Related]
33. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
Bruhn O; Cascorbi I
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1337-54. PubMed ID: 25162314
[TBL] [Abstract][Full Text] [Related]
34. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
[TBL] [Abstract][Full Text] [Related]
35. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2.
Ripperger A; Benndorf RA
Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388
[TBL] [Abstract][Full Text] [Related]
36. Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
Kim CO; Cho SK; Oh ES; Park MS; Chung JY
J Cardiovasc Pharmacol; 2012 Jul; 60(1):49-54. PubMed ID: 22494992
[TBL] [Abstract][Full Text] [Related]
37. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Tan KW; Cooney J; Jensen D; Li Y; Paxton JW; Birch NP; Scheepens A
Mol Nutr Food Res; 2014 Nov; 58(11):2099-110. PubMed ID: 25044854
[TBL] [Abstract][Full Text] [Related]
38. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells.
Wu AM; Dalvi P; Lu X; Yang M; Riddick DS; Matthews J; Clevenger CV; Ross DD; Harper PA; Ito S
Mol Pharmacol; 2013 Feb; 83(2):377-88. PubMed ID: 23150485
[TBL] [Abstract][Full Text] [Related]
39. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
Tamura A; Watanabe M; Saito H; Nakagawa H; Kamachi T; Okura I; Ishikawa T
Mol Pharmacol; 2006 Jul; 70(1):287-96. PubMed ID: 16608919
[TBL] [Abstract][Full Text] [Related]
40. Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model.
Tanaka Y; Kitamura Y; Maeda K; Sugiyama Y
J Pharm Sci; 2015 Sep; 104(9):3039-48. PubMed ID: 25639366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
